NCT04744142

Brief Summary

Because of these anabolic properties of ketone bodies and the fact that ketone bodies prevent muscle protein breakdown for gluconeogenesis during energetic stress, ketone bodies can be a promising strategy to prevent or treat skeletal muscle wasting. Therefore, our aim is to investigate the effect of 3HHB intake on muscle wasting and its adverse consequences during a period of caloric restriction in lean females. In addition, we compare the effects of 3HHB intake with a high protein diet, which is currently considered as the best strategy to minimize lean loss during hypo-energetic periods. To end, we aim to investigate the synergistic effects of the intake of 3HHB in combination with a high protein diet.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2018

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2018

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2019

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

January 25, 2021

Completed
14 days until next milestone

First Posted

Study publicly available on registry

February 8, 2021

Completed
Last Updated

February 8, 2021

Status Verified

February 1, 2021

Enrollment Period

12 months

First QC Date

January 25, 2021

Last Update Submit

February 4, 2021

Conditions

Keywords

resting metabolic rateβ-hydroxybutyratecaloric restrictionmuscle massketone ester

Outcome Measures

Primary Outcomes (1)

  • Muscle mass

    The amount of muscle mass loss

    Muscle mass is measured before and after 4 weeks of caloric restriction

Study Arms (4)

Placebo

NO INTERVENTION

Received 10% protein in nutrition + placebo supplement

Ketone

EXPERIMENTAL

Received 10% protein in nutrition + 3x20g B-hydroxybutyrate per day

Drug: Ketone supplementation

High protein

EXPERIMENTAL

Received 30% protein in nutrition + placebo supplement

Dietary Supplement: Increased protein intake

High protein + ketone

EXPERIMENTAL

Received 30% protein in nutrition + 3x20g B-hydroxybutyrate per day

Drug: Ketone supplementationDietary Supplement: Increased protein intake

Interventions

Subjects receive either placebo or ketone ester supplementation

Also known as: Placebo vs ketone supplementation
High protein + ketoneKetone
Increased protein intakeDIETARY_SUPPLEMENT

Subjects receive either normal or increased protein intake

Also known as: Normal vs increased protein intake
High proteinHigh protein + ketone

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemales
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Females between 18 and 40 years old
  • Fat percentage between 16 and 25%
  • Regularly involved in physical activity ( \> 6 h/week)
  • Use of hormonal contraceptives
  • Good health status confirmed by a medical screening
  • Stable body weight during the last 3 months prior to the study, i.e. no changes \> 2 kg

You may not qualify if:

  • Smoking
  • Obsessive pursuit for thinness, evaluated by the Eating Disorder Inventory 3 (EDI-3) 'Pursuit of leanness' (i.e a score higher than 26/32) (see Appendix 5)
  • Intake of any medication or nutritional supplement that is proven to affect exercise performance, except oral contraceptives
  • Blood donation during the study
  • Current participation in another research trial
  • Any other argument to believe that the subject is unlikely to successfully complete the full study protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

KU Leuven

Leuven, Vlaams-brabant, 3000, Belgium

Location

MeSH Terms

Conditions

Muscular AtrophyKetosis

Condition Hierarchy (Ancestors)

Neuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and SymptomsAcidosisAcid-Base ImbalanceMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Katrien Koppo, PhD

    KU Leuven

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Subjects were randomized by an external, independent researcher. Supplements were color and taste matched.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Subjects were pair-matched for body weight, % body fat and energy intake, where after they were randomly allocated to an experimental group
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

January 25, 2021

First Posted

February 8, 2021

Study Start

January 1, 2018

Primary Completion

December 20, 2018

Study Completion

June 1, 2019

Last Updated

February 8, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will not share

Results will be published in internationally peer-reviewed journals

Locations